The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Characterization of an anti-Trop-2-SN-38 antibody-drug conjugate (IMMU-132) with potent activity against solid cancers.
David M. Goldenberg
Employment or Leadership Position - Immunomedics
Stock Ownership - Immunomedics
Edmund A Rossi
Employment or Leadership Position - Immunomedics
Serengulam V. Govindan
Employment or Leadership Position - Immunomedics
Thomas M. Cardillo
Employment or Leadership Position - Immunomedics
William J. McBride
Employment or Leadership Position - Immunomedics
Stock Ownership - Immunomedics
Maria Zalath
Employment or Leadership Position - Immunomedics
Gaby Terracina
Employment or Leadership Position - Immunomedics
Preeti Trisal
Employment or Leadership Position - Immunomedics
Robert M. Sharkey
Employment or Leadership Position - Immunomedics